PAA is preparing to start a pivotal field trial in dogs with B-Cell
Lymphoma to enable product registration in the US in 2025. PAA has previously successfully completed a Phase
1 oncology clinical study of monepantel in humans and pilot studies in canine cancer.
Oh yeahh? Pilot Studies in K9's ,, where's the Commercial Outcome for CY 2023 Roger? Company made 3 ASX Announcements that state this in 2022/2023.... how did all those interested Parties go? now looking at 2025?? sure
Ann: 93% take up in Options Offer, page-5
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $82.69M | |||
| Open | High | Low | Value | Volume |
| 17.0¢ | 17.0¢ | 16.3¢ | $108.2K | 647.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 109170 | 16.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.0¢ | 117939 | 4 |
View Market Depth
| Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
| PAA (ASX) Chart |